Chronic Kidney Disease
Chronic Kidney Disease Content
Chronic kidney disease in patients with type 2 diabetes: What is the place for mineralocorticoid receptor antagonists?
Watch interviews with three internationally recognized experts about the role of mineralocorticoid receptor antagonists in the treatment and prevention of chronic kidney disease in patients with type 2 diabetes.
- Describe novel approaches to targeting inflammation and fibrosis for the treatment of chronic kidney disease in type 2 diabetes
- Describe the rationale for targeting the mineralocorticoid receptor for the treatment of chronic kidney disease in type 2 diabetes
- Discuss clinical trial data for novel mineralocorticoid receptor antagonists for the treatment of chronic kidney disease in patients with type 2 diabetes
Hyperinsulinaemic Hypoglycaemia and Polycystic Kidney Disease – A Rare Case Concerning PMM2 Gene Pleiotropy
European Endocrinology. 2020;16(1):66-8
Hyperinsulinaemic Hypoglycaemia (HH) is a very rare disease with an estimated incidence of 1/50,000,1 and includes a clinical, histological and genetic heterogeneous group of disorders characterised by hypoglycaemia, hyperinsulinism or, more specifically, increased C-peptide level and inappropriate low blood levels of ketone bodies during a hypoglycaemic event. HH is a variable condition: it can be […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!